Arena's S1PR1 agonist meets in Phase II for UC

Arena Pharmaceuticals Inc. (NASDAQ:ARNA) said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS trial to treat ulcerative colitis.

Arena plans to start a Phase III program for the sphingosine 1-phosphate receptor 1 (S1PR1; S1P1; EDG1) agonist to treat UC, but the company said it is too early to comment on a timeline for when the program is slated to start...